Jw Holdings - Asset Resilience Ratio
Jw Holdings (096760) has an Asset Resilience Ratio of 1.56% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 096760 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2024)
This chart shows how Jw Holdings's Asset Resilience Ratio has changed over time. See 096760 net asset value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Jw Holdings's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 096760 market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩19.24 Billion | 1.56% |
| Total Liquid Assets | ₩19.24 Billion | 1.56% |
Asset Resilience Insights
- Limited Liquidity: Jw Holdings maintains only 1.56% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Jw Holdings Industry Peers by Asset Resilience Ratio
Compare Jw Holdings's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC |
Drug Manufacturers - Specialty & Generic | 43.05% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 1.96% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Guobang Pharma Ltd
SHG:605507 |
Drug Manufacturers - Specialty & Generic | 8.47% |
Annual Asset Resilience Ratio for Jw Holdings (2007–2024)
The table below shows the annual Asset Resilience Ratio data for Jw Holdings.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 2.41% | ₩30.14 Billion ≈ $20.43 Million |
₩1.25 Trillion ≈ $847.52 Million |
-4.44pp |
| 2023-12-31 | 6.85% | ₩80.61 Billion ≈ $54.62 Million |
₩1.18 Trillion ≈ $797.14 Million |
-2.00pp |
| 2022-12-31 | 8.85% | ₩102.48 Billion ≈ $69.45 Million |
₩1.16 Trillion ≈ $784.48 Million |
+3.47pp |
| 2021-12-31 | 5.39% | ₩57.41 Billion ≈ $38.91 Million |
₩1.07 Trillion ≈ $722.26 Million |
+0.34pp |
| 2020-12-31 | 5.04% | ₩56.44 Billion ≈ $38.25 Million |
₩1.12 Trillion ≈ $758.15 Million |
+4.05pp |
| 2019-12-31 | 0.99% | ₩12.36 Billion ≈ $8.38 Million |
₩1.24 Trillion ≈ $842.68 Million |
-0.80pp |
| 2018-12-31 | 1.79% | ₩22.83 Billion ≈ $15.47 Million |
₩1.28 Trillion ≈ $864.48 Million |
+0.58pp |
| 2017-12-31 | 1.21% | ₩16.40 Billion ≈ $11.12 Million |
₩1.35 Trillion ≈ $915.81 Million |
-2.93pp |
| 2016-12-31 | 4.15% | ₩49.63 Billion ≈ $33.64 Million |
₩1.20 Trillion ≈ $810.94 Million |
+3.89pp |
| 2015-12-31 | 0.26% | ₩2.76 Billion ≈ $1.87 Million |
₩1.08 Trillion ≈ $733.84 Million |
-0.03pp |
| 2014-12-31 | 0.28% | ₩2.93 Billion ≈ $1.98 Million |
₩1.04 Trillion ≈ $702.09 Million |
-0.10pp |
| 2013-12-31 | 0.38% | ₩3.84 Billion ≈ $2.60 Million |
₩1.01 Trillion ≈ $687.47 Million |
+0.07pp |
| 2012-12-31 | 0.31% | ₩3.29 Billion ≈ $2.23 Million |
₩1.08 Trillion ≈ $729.96 Million |
+0.01pp |
| 2011-12-31 | 0.29% | ₩3.20 Billion ≈ $2.17 Million |
₩1.09 Trillion ≈ $741.92 Million |
-0.17pp |
| 2010-12-31 | 0.46% | ₩3.41 Billion ≈ $2.31 Million |
₩736.86 Billion ≈ $499.36 Million |
-0.13pp |
| 2009-12-31 | 0.59% | ₩4.17 Billion ≈ $2.83 Million |
₩709.64 Billion ≈ $480.91 Million |
-1.76pp |
| 2008-12-31 | 2.35% | ₩15.08 Billion ≈ $10.22 Million |
₩642.09 Billion ≈ $435.13 Million |
-3.11pp |
| 2007-12-31 | 5.46% | ₩30.30 Billion ≈ $20.54 Million |
₩554.89 Billion ≈ $376.04 Million |
-- |
About Jw Holdings
JW Holdings Corporation, together with its subsidiaries, operates as a healthcare company in South Korea, the United States, Japan, China, and internationally. The company offers amino acid solutions, gastrointestinal agents, wound care, eye care, liver disease treatment, cold medicine, API, oral and topical analgesic, and other miscellaneous pharmaceutical products. It also offers hairdye, hair … Read more